TPG and CPPIB affiliates complete acquisition of IMS Health

NewsGuard 100/100 Score

IMS Health, the world’s leading provider of market intelligence to the pharmaceutical and healthcare industries, today announced the completion of its acquisition by entities created by certain affiliates of TPG Capital, L.P. (“TPG”) and the CPP Investment Board (“CPPIB”).

“As a private company, we will continue to innovate for client needs and look forward to working with our new partners as we capitalize on our expanding opportunity in the healthcare market.”

“This transaction has delivered significant value to our shareholders and is a strong endorsement of our business model, our teams and the leadership position we have built,” said IMS Health Chairman and CEO David R. Carlucci. “As a private company, we will continue to innovate for client needs and look forward to working with our new partners as we capitalize on our expanding opportunity in the healthcare market.”

“We are delighted to be working with the talented IMS management team to drive growth by expanding the company’s market intelligence offerings, which are crucial to the healthcare industry,” said James Coulter, founding partner, TPG.

Mark Wiseman, senior vice-president, Private Investments, CPP Investment Board said, “IMS is a world-class company with a strong management team and excellent growth prospects. We look forward to working with management to position IMS for success over the long term.”

Pursuant to the terms of the merger agreement, IMS Health’s stockholders are entitled to receive $22.00 in cash, without interest, less any applicable withholding taxes, for each share of IMS Health common stock owned by them. As a result of the merger, IMS Health’s common stock will no longer be listed for trading on the New York Stock Exchange.

Stockholders of record will receive a letter of transmittal and instructions on how to surrender their shares of IMS Health common stock in exchange for the merger consideration. Stockholders of record should wait to receive the letter of transmittal before surrendering their shares.

Source:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
AI technologies can accurately identify cases of healthcare-associated infections